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A b s t r a c t 
Introduction: Low vitamin  D levels have been recognised as an important 
risk factor for autoimmune diseases, including multiple sclerosis (MS). MS 
is a  multifactorial  disease, the pathogenesis of which contributes both to 
genetic and environmental factors. Polymorphisms in genes codifying mole-
cules involved in vitamin D homeostasis have been associated with hypovit-
aminosis D. However, the influence of polymorphisms of Klotho, which codify 
a protein with a pivotal role in vitamin D metabolism, have never been in-
vestigated. The aim of this study was to evaluate the association among ge-
netic variants of Klotho, namely rs1207568 and rs9536314, serum 25(OH)D3 
levels, and multiple sclerosis (both risk and disease progression). 
Material and methods: 107 patients with MS and 133 healthy controls were 
enrolled in this study. Serum 25(OH)D3 levels and genotyping of Klotho SNPs 
were evaluated in all participants by high-performance liquid chromatogra-
phy and real-time polymerase chain reaction, respectively.
Results: Allelic and genotypic frequencies did not differ between patients 
and controls. Concerning rs1207568, we found a trend toward lower serum 
25(OH)D3 levels in MS patients with A allele (mutant), both in heterozygosis 
(AG) and in homozygosis (AA), in comparison to MS patients with G allele 
in homozygosis (GG) (AG + AA 20.5 ±6.3 μg/l; GG 22.5 ±7.5 μg/l, p = 0.07).
Conclusions: Our findings  did not identify a  role of Klotho in the genetic 
susceptibility to MS. 
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Introduction 
Multiple sclerosis (MS) is a chronic inflammatory, autoimmune disease 
of the central nervous system (CNS) characterised by demyelination and 
axonal degeneration. It is the commonest non-traumatic disabling dis-
ease affecting young adults [1]. MS is generally recognised as a  T-cell 
mediated  disease, but the exact underlying causes are not completely 
understood. It is currently considered a  very heterogeneous  disorder 
in which both genetic-susceptibility and environmental exposures are 
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strongly implicated in the activation of T cells and 
MS-pathogenesis [2]. Current research is focused 
on the identification of risk factors. In the last dec-
ades, a role of hypovitaminosis D has emerged [3]. 
Since the  discovery of vitamin  D immunomodu-
latory function, vitamin  D has been proposed as 
a  serum biomarker in several clinical conditions, 
including neurodegenerative disorders, along with 
inflammatory and cardiovascular markers [4–16]. 
It is well recognised that patients affected by 
MS usually have lower vitamin D levels than the 
general population [17]. However, the question 
that needs to be addressed is whether low vita-
min D levels contribute to MS pathogenesis or if 
they stem from it. Preliminary hypothesis support-
ed that hypovitaminosis D is the result of inade-
quate sun exposure due to the physical disability 
related to MS [18], but a  great  deal of evidence 
from epidemiological and experimental studies 
supports the pathogenic role of vitamin D [19–21]. 
On the one hand, prospective epidemiological 
studies have shown that elevated serum vitamin D 
levels are associated with a decreased risk for de-
veloping MS later in life among healthy young 
adults [22] and with reduced clinical activity in 
established MS patients [23]; on the other hand, 
experimental studies revealed that the biologi-
cally active form of vitamin  D, namely 1,25-dihy-
droxy-vitaminD3 [1,25(OH)2D3], exerts an immuno-
modulatory action, controlling both adaptive and 
innate immunity, as well as a neuroprotective role 
[10, 24–28].
A lot of evidence supports the hypothesis that 
low vitamin  D levels are the result of both envi-
ronmental and genetic factors [22]. Concerning 
the role of genetics, Genome Wide Association 
Studies (GWAS) have identified variants in genes 
codifying molecules involved in vitamin D metab-
olism that have been confirmed in gene-candi-
date studies [29–32]. Among regulators of vita-
min D metabolism, Klotho plays a prominent role. 
Klotho is a  protein casually identified by Kuro-o   
et al. [33] in 1997 during experiments on transgen-
ic mice. Klotho is a  transmembrane glycoprotein 
with a  large extracellular domain and a short cy-
tosolic domain (≈10 aa). It exists in two isoforms 
with  distinct biological function: transmembrane 
and soluble. The latter  derives from alternative 
splicing or proteolytic cleavage of transmembrane 
Klotho by membrane protease (ADAM 10 and 17). 
Soluble Klotho is  detectable in blood, urine, and 
cerebrospinal fluid (CSF) [34], and it acts as a hu-
moral factor influencing several cellular process-
es [35, 36]. Transmembrane Klotho functions as 
a co-receptor for fibroblast growth factor-receptor 
(FGF-R) and provides selective binding affinity to 
FGF-23. The complex Klotho/FGF-R/FGF-23 is in-
volved in vitamin D homeostasis [37]. In particu-
lar, vitamin D and Klotho biological functions are 
highly intertwined because vitamin  D controls 
the expression of Klotho, and Klotho feeds back 
to inhibit the 1α-hydroxylase (CYP27B1), which 
converts 25-hydroxy-vitaminD
3 [25(OH)D3] to the 
biologically active form, 1-25(OH)
2D3, and to in-
duce the activity of the 24-hydroxylase (CYP24A1), 
which converts both 25(OH)D
3 and 1-25(OH)2D3 in 
24-hydroxylated products targeted for excretion 
(Figure 1) [35, 38]. Thus, genetic variants of Klotho 
associated with an alteration of its levels or its bi-
ological function could lead to hypovitaminosis D 
and, consequently, to an increased risk of several 
pathological conditions. The aim of our study was 
to evaluate the relationship among Klotho genetic 
variants, vitamin D status, and multiple sclerosis. 
Material and methods 
This was an observational, retrospective, case- 
control study including 107 patients with MS and 
133 healthy subjects. Patients and controls were 
recruited from 2013 to 2016 from the department 
of Experimental Biomedicine and Neuroscience, 
Figure 1. Axis Klotho/FGF-23/vitamin D
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University of Palermo, and from the Unit of Trans-
fusion Medicine of Villa Sofia-Cervello of Palermo. 
An expert neurologist made the diagnosis of mul-
tiple sclerosis according to revised McDonald cri-
teria [39]. The neurological status of patients was 
assessed using Kurtzke’s Expanded disability Sta-
tus Scale (EDSS), the most common clinical scoring 
system, ranging from 0 (normal) to 10 (death due 
to MS) in half-point increments [40]. The progres-
sion of disability was assessed using the Multiple 
Sclerosis Severity Score (MSSS) [41]. The annual-
ised relapse rate (ARR) was calculated in the year 
prior the genotyping. 
The research institute’s committee on human 
research approved the study protocol. All partici-
pants gave their written, informed consent.
MS patients comprised 26 men and 81 women 
with a mean age 39.8 ±9.9 years. Controls were 70 
men and 63 women with a mean age of 44 ±9.9 
years. Table I shows the demographic and clinical 
characteristics of study groups. 
All samples were genotyped by Real-Time allel-
ic  discrimination TaqMan assay (Applied Biosys-
tems). Genomic DNA was purified from 200 μl of 
whole peripheral blood using the QIAamp blood 
minikit (Qiagen, Valencia, CA, USA). DNA samples 
were quantified by spectrophotometric  deter-
mination; aliquots of  DNA were stored at –20°C 
for subsequent analysis. We selected two Single 
Nucleotide Polymorphisms (SNPs) in KLOTHO, the 
rs1207568 (G-395A) in the promoter region and 
the rs9536314 (F352V) in exon 2. Genotyping 
for rs1207568 and rs9536314 was carried out by 
the Taqman SNP genotyping allelic  discrimina-
tion method on a 7500 real-time PCR system. The 
PCR reaction mix consisted of 25 ng of DNA, 5 μl 
TaqMan Genotyping Master Mix, and 0.25 μl ge-
notyping assay mix and distilled water for a final 
volume of 20 μl. Cycling conditions for amplifica-
tion were 60°C for 30 s, 95°C for 10 min, 40 cycles 
as follows: 95°C for 15 s and 60°C for 1 min, and 
a final step at 60°C for 30 s (Applied Biosystems).
25(OH)D
3 levels were measured on serum of 
both patients and controls. Serum tubes were 
centrifuged immediately after the collection, and 
serum was stored at –20°C until the analysis. 
25(OH)D3 levels were quantified using a Chromo-
system reagent kit (Chromsystems Instruments & 
Chemicals) on an isocratic high-performance liquid 
chromatography (HPLC) system with a UV detec-
tor. In accordance with the recommendation of the 
Institute of Medicine [42], optimal serum 25(OH)
D
3 levels were defined as > 30 ng/ml; 20–30 ng/ml 
and < 20 ng/ml indicated vitamin D insufficiency 
and deficiency, respectively. 
Statistical analysis
Statistical analysis was performed using SPSS 
software (version 13.0). All genotypes were tested 
for Hardy-Weinberg equilibrium using χ2 test. Al-
lelic and genotypic frequencies of rs1207568 and 
rs9536314 were compared between patients and 
controls by Fisher’s exact test. Quantitative results 
are expressed as the mean ± standard deviation. 
A p-value < 0.05 was considered statistically sig-
nificant. 
Results 
The genotypic frequencies of rs1207568 and 
rs9536314 were found to be in Hardy-Weinberg 
equilibrium in both study groups. Genotypic 
and allelic frequency  distributions of both SNPs 
are displayed in Table II. We did not find associa-
tions between alleles and genotypes and multiple 
sclerosis. Furthermore, no significant  differences 
Table I. Demographic and clinical characteristics of 
patients and controls 
Parameter Cases  
(n = 107) 
Controls  
(n = 133)
Age [years] 39.8 ±9.9 44 ±9.9*
Sex, n (male/female) 26/81 70/63
Disease Duration [years] 11.6 ±9.8  –
Age of MS onset [years] 28.0 ±7.9  –
MS-type (n) RR/SP/PP 92/14/1  –
EDSS 3.0 ±2.2  –
MSSS 3.8 ±2.7  –
ARR 1.25 ±0.96  –
Data are shown as: mean ± SD. *p < 0.05. EDSS – Expanded Disability 
Status Scale, MSSS – Multiple Sclerosis Severity Score, ARR – 
annualised relapse rate. 
Table II. Association analysis of Klotho polymor-
phisms in MS patients and controls
Polymorphisms MS patients  
(n = 107)
Controls  
(n = 133)
rs9536314:
TT 80 (75%) 93 (70%)
GT 24 (22%) 35 (26%)
GG 3 (3%) 5 (4%)
G 30 (14%) 45 (17%)
T 184 (86%) 221 (83%)
rs1207568:
GG 74 (69%) 84 (63%)
AG 30 (28%) 42 (32%)
AA 3 (3%) 7 (5%)
G 178 (83%) 210 (79%)
A 36 (17%) 56 (21%)
P-value > 0.05.
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between MS patients and controls were  detect-
ed using dominant and recessive genetic models 
(data not shown). Among MS patients, the analysis 
of the effect of the SNPs on age of disease onset, 
EDSS, MSSS, and ARR did not reveal any effect of 
them on disease course. As previously shown [31, 
32], we found that serum 25(OH)D
3 levels were 
significantly lower in MS patients than in controls 
(21.8 ±7.2 μg/l and 39.1 ±9.3 μg/l, respectively; 
p < 0.001). In particular, vitamin  D insufficiency 
was prevalent in MS patients (59%); 26% had vita-
min D deficiency, and only 15% had optimal levels 
(Figure 2). Interestingly, when stratifying MS pa-
tients according to SNPs, for rs1207568 we found 
a  trend toward decreased serum 25(OH)D3 levels 
in AG and AA vs. GG patients (AG + AA 20.5 ±6.3 
μg/l; GG 22.5 ±7.5 μg/l, p = 0.07); AA patients had 
the lowest 25(OH)D
3 levels (17.6 ±8 μg/l) (p > 0.05) 
(Figure 3).
Discussion
In order to better understand how genetics can 
influence vitamin  D metabolism in MS patients, 
we evaluated the impact of two polymorphisms of 
Klotho, one regulatory (rs1207568) and one func-
tional (rs9536314), in relation to serum 25(OH)D3 
levels in patients with multiple sclerosis and 
healthy subjects; both polymorphisms have nev-
er been studied in multiple sclerosis. Our findings 
revealed no association of both Klotho polymor-
phisms with MS susceptibility and severity. Re-
markably, MS patients harbouring the A allele (mu-
tant) of rs1207568 – both in homozygosis and in 
heterozygosis – had lower serum 25(OH)D3 levels 
than GG patients. 
Klotho is a multifunctional protein, which plays 
a pivotal role in vitamin D metabolism [43]. In vivo 
studies showed that KLOTHO knockout mouse had 
severe hypervitaminosis D, which was rescued by 
vitamin D restriction [44, 45]. The increase of vita-
min D levels in Klotho-deficient mice was a conse-
quence of the increased activity of CYP27B1 and 
reduced activity of CYP24A1, which are physiologi-
cally regulated by Klotho [46]. 
Klotho gene maps on chromosome 13q12, and 
it consist of five exons and four introns [47]. GWAS 
studies have identified polymorphisms in both 
coding and non-coding regions of the Klotho gene 
associated with increased risk of  diseases such 
as  diabetes and cardiovascular  diseases [48–51]. 
To date, no data are available regarding the role of 
the Klotho polymorphisms in MS risk. The Klotho 
SNPs investigated in this study, namely rs1207568 
and rs9536314, have been selected from literature 
for their functional role in altering protein product 
(rs1207568) or amino acid (rs9536314). Both SNPs 
have been associated with an alteration of levels 
or catalytic activity of Klotho. The SNP rs9536314 
is a  missense variant and belongs to the KL-VS 
haplotype. The latter represents a functional vari-
ant composed of six SNPs in perfect linkage dis-
equilibrium and spans exon 2 and its flanking 
sequence [52]. Among these SNPs, the rs9536314 
and the rs9527025 result in amino acid substi-
tution – F352V and C370S, respectively. “KL-VS” 
alludes to the V and S substitution of these two 
SNPs. The SNP rs9536314 can be used to evaluate 
the entire haplotype because all six SNPs are in 
linkage disequilibrium. 
The rs1207568 (G-395A) is one of the SNPs lo-
cated in the promoter region of the KLOTHO gene, 
near the 5′UTR [53]. In vitro studies reported that 
the rs1207568 is associated with a higher promot-
er activity [54] upregulating its expression. Hao 
et al. hypothesised that this variant could enhance 
the levels or activity of Klotho [55]. The KL-VS 
variant, instead, induces an increase of the cata-
lytic activity of Klotho. Consequently, both genetic 
Figure 2. Vitamin D status in multiple sclerosis pa-
tients
 Sufficiency         Insufficiency         Deficiency
26%
15%
59%
 AA GG
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Figure 3. 25(OH)D3 levels in MS patients stratified 
according to rs1207568 genotype 
AA – mutant, GG – wildtype.
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variants could be associated with a reduced acti-
vation of 25(OH)D3 and an increased degradation 
of both 25(OH)D
3 and 1,25(OH)2D3. Indeed, Klotho 
induces the  down-regulation of CYP27B1, the vi-
tamin D-activating enzyme, and the up-regulation 
of CYP24A1, the vitamin  D-deactivating enzyme. 
However, functional studies are mandatory to sup-
port this hypothesis. 
Ellidag et al. showed an alteration of the axis 
Klotho/FGF-23/vitamin D in MS patients and un-
derlined its importance on the pathogenesis of 
the disease. In particular, they found higher levels 
of Klotho and lower levels of 25(OH)D
3 in MS pa-
tients than in controls [37]. However, the influence 
of Klotho variants on vitamin  D metabolism has 
never been investigated in MS patients. 
Previously, we explored the association among 
SNPs in several genes involved in vitamin D me-
tabolism, multiple sclerosis, and vitamin D status, 
revealing a role of genetic variants of VDR, CYP2R1, 
and CYP24A1 in MS risk and progression [31, 32, 
56, 57]. The findings of the present study failed to 
identify a role of Klotho in either the genetic sus-
ceptibility or the progression of multiple sclerosis. 
Of note, we found that the rs1207568 is associat-
ed with reduced serum 25(OH)D3 levels.
Our study has some limitations, including the 
small sample and the case-control study  design. 
Thus, we cannot rule out the role of Klotho in MS 
risk, and large-scale studies are needed to address 
this. 
In conclusion, our findings  did not identify 
a role of genetic variants of Klotho in MS risk and 
progression. 
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